PIK3CA and neoplasm: Importantly, while the Syk-PI3Kγ axis in macrophages has been reported to inhibit antitumor immunity, SRX3207, a novel dual Syk-PI3K inhibitor, has been shown to block these inhibitory effects, thereby relieving tumor immunosuppression [161].